Medical
UK
Europe

NovoCure

$70.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.09 (1.57%) Today
$0.00 (0.00%) As of 4:06 PM EDT after-hours

Why Robinhood?

You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!

About NVCR

NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Employees
598
Headquarters
St. Helier, Jersey
Founded
2000
Market Cap
6.64B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
697.85K
High Today
$71.79
Low Today
$69.90
Open Price
$71.20
Volume
656.72K
52 Week High
$72.59
52 Week Low
$26.02

Collections

Medical
UK
Europe
Health
Cancer Prevention
Technology
2015 IPO

NVCR Earnings

-$0.23
-$0.18
-$0.12
-$0.07
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.07 per share
Actual
Available Jul 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.